Bevacizumab (BEV), a vascular endothelial growth factor (VEGF)-targeting monoclonal antibody, disrupts tumor angiogenesis and normalizes aberrant vasculature, potentially enhancing radiotherapy efficacy.[9] Recent meta-analyses have demonstrated that BEV combined with radiotherapy improves objective response rates (48% vs 28%) and reduces peritumoral edema in NSCLC BM.[10] However, its role in epidermal growth factor receptor (EGFR)/anaplastic lymphoma kinase (ALK) wild-type LUAD remains to be explored. This evidence concerns the gene ALK and neoplasm.